Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...

Boston Scientific’s BSX Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% over the 2026-2028 long-range plan (LRP). Management expects the business to outpace ...

(Reuters) - Boston Scientific Corp expects more hospitals will be able to offer its new atrial fibrillation treatment starting by the end of the third quarter as it paces the product's rollout to give ...

17 deaths and 120 serious injuries have been reported due to complications during Watchman procedures. Boston Scientific warned Watchman customers of a higher risk of complications during procedures ...